Navigation Links
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Date:10/25/2007

8 million and $3.9 million, respectively, for the third quarter and nine-months ended September 30, 2007 as a reduction in the number of active independent distributor representatives reflects the effects of ongoing litigation, which the Company is vigorously pursuing with the sponsor of the Company's product line in this segment. Corrective actions continue to be taken to resolve the litigation and increase the number of active independent distributor representatives as part of strategic efforts with the goal to increase sales and return to profitability.

No tax provision or benefits, to reduce losses, are provided for the quarter and nine-months ended September 30, 2007 and 2006, except for any requirements imposed by the federal alternative minimum taxes or for compliance with state tax regulations, since the Company is in a net operating loss carry-forward position.

The research by the Company is part of its strategic initiatives to generate future growth. These initiatives include capitalizing on the growth potential of Quigley Pharma, a wholly-owned Ethical Pharmaceutical subsidiary, by developing natural-source potential prescription products for Systemic Radiation, Rheumatoid Arthritis, Avian Flu in animals and particularly, Diabetic Peripheral Neuropathy.

During the third quarter of 2007, a human safety study was undertaken to investigate the effects of QR-449, a broad spectrum anti-inflammatory compound, on patients suffering from Metabolic Syndrome, a condition which inhibits normal metabolic processes. Metabolic Syndrome sufferers are vulnerable to dangerous heart attack risk factors including diabetes, abdominal obesity, high cholesterol and high blood pressure. Inflammation plays a major role in this condition as well as Rheumatoid Arthritis, Cancer and Cachexia.

The primary objectives for the study are the determination of safety and to measure the corrective capacity of the compound on the imbalance of important anti-oxidant,
'/>"/>

SOURCE The Quigley Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014  NxStage ® ... leading manufacturer of innovative dialysis products , ... Express dialyzer for the in-center, hemodialysis market. ... which is designed to reduce the amount of ... the number of touch point contamination sites.  The ...
(Date:11/18/2014)... N.J. , Nov. 18, 2014 ... 230,000 American women this year who get a ... today announced new resources for case managers to ... and 5—to navigate the myriad physical, emotional and ... resources are available at no cost via the ...
(Date:11/18/2014)... , Nov. 18, 2014  TransCelerate BioPharma ... most recent manuscript on Risk-Based Monitoring (RBM), ... Quality Control Measure in Clinical Trials ," ... Innovation & Regulatory Science  (TIRS) journal. Developed ... with Medidata, the manuscript examines the value ...
Breaking Medicine Technology:NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2New Breast Cancer Resources: Commission For Case Manager Certification Adds Specialty Tools to Case Management Body of Knowledge Online Learning Center 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 3
... - Ambrilia,Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing,novel ... and,cancer, held its Annual General and Special Meeting ... novel series of HIV,integrase inhibitors and recent developments ... Chairman of the Board, Mr. Frederic,Porte, and a ...
... 2007 /PRNewswire/ -- Results of the,Option (TOcilizumab ... first multinational Phase III study outside,of Japan, ... 4mg/kg,or 8mg/kg) plus methotrexate achieved a significant ... symptoms of moderate to,severe rheumatoid arthritis (RA) ...
Cached Medicine Technology:Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 3Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5
(Date:11/21/2014)... (PRWEB) November 21, 2014 Porcelain ... picture-perfect smiles for patients in preparation for the coming ... the fronts of teeth, look completely natural, and can ... situations, veneers are also valued for their ability to ... and can be used on one or several teeth ...
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- Seeking to make it ... Food and Drug Administration on Thursday approved a new ... Hydrocodone -- best known by the brand name Vicodin ... tied to a surge in dangerous addictions across the ... Hysingla ER (hydrocodone bitartrate) is an extended-release tablet to ...
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- Certain genes might prevent ... to a fifth of people with type 2 diabetes, ... been pondered by doctors working with diabetic patients, one ... under the impression that exercise helps decrease insulin resistance ... Pena, director of the Center for Weight Management at ...
(Date:11/21/2014)... 21, 2014 Richard Wolfe, co-founder ... will present advanced benefits administration strategies during the ... HR Leadership Summit. This Game Changer breakout session ... to present cutting-edge solutions and best practices to ... how real-time data exchange between health and welfare ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Center for ... workshops titled “Massachusetts Insurance Funding for Autism Workshops” to ... navigate their way through the insurance coverage process. ... Massachusetts law and the most effective ways to access ... Dec. 4 from 6-8:00 p.m. at 331 Montvale Ave., ...
Breaking Medicine News(10 mins):Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2
... tests for liver fibrosis, such as liver stiffness measurement ... chronic hepatitis C, according to a new study in ... Gastroenterological Association (AGA) Institute. "Liver stiffness measurement ... evaluation of hepatitis C, regardless of the stage of ...
... 2020 strategy and its Innovation Union flagship initiative, the ... cooperation activities and how EUREKA could contribute to strengthening ... in the regions. High-level stakeholders and all interested ... conference,s discussions which will have a significant role in ...
... HealthDay Reporter , MONDAY, June 13 (HealthDay News) ... even though most people agree the government-sponsored health insurance program ... survive. Instead, respondents to a Harris ... should be shored up, in part, by lowering the fees ...
... sleep problems with cognitive-behavioral therapy for insomnia can reduce ... presented Tuesday, June 14, in Minneapolis, Minn., at SLEEP ... Sleep Societies LLC (APSS). Results show that about ... reported having suicidal thoughts or wishes during the past ...
... sleep per night is associated with higher ratings for quality ... abstract that will be presented Tuesday, June 14, in Minneapolis, ... Associated Professional Sleep Societies LLC (APSS). Results show that ... hours per night had higher self-reported scores for quality of ...
... By Randy Dotinga HealthDay Reporter , MONDAY, June ... help children solve problems more easily, a goal that can ... study suggests. The research doesn,t suggest that ordinary video ... how a particular type of training can boost brain skills ...
Cached Medicine News:Health News:Noninvasive liver tests may predict hepatitis C patient survival 2Health News:Poll Finds Little Support for GOP Plan to Privatize Medicare 2Health News:Poll Finds Little Support for GOP Plan to Privatize Medicare 3Health News:Cognitive-behavioral therapy for insomnia can reduce suicidal ideation 2Health News:The good life: Good sleepers have better quality of life and less depression 2Health News:Training via Video Game Shown to Boost Kids' Brain Power 2Health News:Training via Video Game Shown to Boost Kids' Brain Power 3
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Ballard trach care HMES and filters, universal use, "Y" filter, CO 2 sampling port...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
Medicine Products: